Antengene

Antengene, a Pharmaceutical Preparation Manufacturing company headquartered in China, reported total direct and indirect (Scope 1 and 2) greenhouse gas emissions of approximately 1,169,980 kg CO2e for 2023. This included approximately 45,220 kg CO2e from Scope 1 emissions and 1,124,760 kg CO2e from Scope 2 emissions.

In 2022, their Scope 1 emissions were about 551,320 kg CO2e, and Scope 2 emissions were around 1,061,940 kg CO2e, totalling approximately 1,613,260 kg CO2e. For 2021, Antengene's Scope 1 emissions were approximately 27,080 kg CO2e, and Scope 2 emissions were roughly 967,300 kg CO2e, resulting in a combined Scope 1 and 2 total of approximately 994,380 kg CO2e. In 2020, their Scope 1 emissions were about 27,080 kg CO2e, and Scope 2 emissions were approximately 251,390 kg CO2e, with a combined Scope 1 and 2 total of roughly 278,470 kg CO2e. The company has not disclosed Scope 3 emissions data.

Antengene has reported GHG emission intensities, including approximately 50 kg CO2e per square metre and 6,430 kg CO2e per employee in 2023. In 2022, these figures were roughly 70 kg CO2e per square metre and 7,230 kg CO2e per employee. For 2021, the intensity was approximately 50 kg CO2e per square metre and 5,290 kg CO2e per employee. In 2020, the GHG emission intensity was about 15 kg CO2e per square metre. Antengene has not publicly disclosed specific climate reduction targets or commitments.